The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Choosing Between TAS-102 and Regorafenib in Colorectal Cancer

Cathy Eng, MD, FACP
Published Online:3:03 PM, Thu November 30, 2017

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.